Artificial intelligence (AI)-powered protein models combined with genome sequencing technology could help scientists better ...

1910 Genetics' platform differs from other players because its AI and computational platforms – ELVIS for small molecules and ROSALYND for proteins – is driven by biological properties like ...

Colossal Biosciences' claim to have achieved the 'de-extinction' of the dire wolf has been questioned by geneticists, but the ...

Worldwide, The development of hormone-free In Vitro Fertilisation, direct-thaw frozen embryo programs and greatly improved ...

The integration of AI healthcare solutions into modern medicine marks a transformative shift that is reshaping clinical practices and patient outcomes. This technology has rapidly evolved from ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment? Let's see.

Stocks recently featured in the blog include: Tempus AI TEM, AstraZeneca AZN, iRhythm Technologies IRTC and SOPHiA GENETICS SOPH. Here are highlights from Thursday’s Analyst Blog: Tempus AI ...